Holen Sie sich die Stockscreener-App
109.07
0.86%
-1.16
Schlusskurs vom Vortag:
$110.23
Offen:
$108.18
24-Stunden-Volumen:
217.39K
Relative Volume:
0.21
Marktkapitalisierung:
$27.42B
Einnahmen:
$3.53B
Nettoeinkommen (Verlust:
$-632.54M
KGV:
-41.48
EPS:
-2.6296
Netto-Cashflow:
$-588.89M
1W Leistung:
-0.59%
1M Leistung:
+0.37%
6M Leistung:
+8.61%
1J Leistung:
-3.22%
1-Tages-Spanne:
$107.00
$110.10
1-Wochen-Bereich:
$107.00
$112.40
52-Wochen-Spanne:
$81.20
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
109.28 | 27.66B | 3.53B | -632.54M | -588.89M | -2.6296 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.31 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.00 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
757.80 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.64 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
311.42 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Hochstufung | Goldman | Neutral → Buy |
| 2025-06-05 | Bestätigt | H.C. Wainwright | Buy |
| 2025-05-29 | Eingeleitet | Goldman | Neutral |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
Primecap Management Co. CA Sells 130,700 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
Moderna, Coinbase, And Global Payments Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio? - Benzinga
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BioNTech’s New HIV Antibody Trial Adds Depth to BNTX’s Long-Term Pipeline Story - TipRanks
BioNTech SE (BNTX) Rallying on Solid Oncology Strategy - Finviz
Aberdeen Group plc Has $28.79 Million Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Strategic Pivot: Key Catalysts on the 2026 Horizon () - aktiencheck.de
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data - The Globe and Mail
BioNTech (NASDAQ:BNTX) Lowered to Market Perform Rating by Leerink Partners - Defense World
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings? - Finviz
Leerink downgrades BioNTech to “market perform” after 24% share rally - Investing.com
Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech and Bristol-Myers Squibb Advance Pumitamig Trial in Aggressive Brain Cancer - TipRanks
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? - Finviz
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline - Finviz
BioNTech SE (BNTX): A Bull Case Theory - Finviz
2 Biotech Stocks Set to Rebound in 2026 - Finviz
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch - TipRanks
BioNTech’s New Phase III Prostate Cancer Trial Adds Long-Term Upside Potential for BNTX - TipRanks
BioNTech SE Sponsored ADR $BNTX Holdings Boosted by Lbp Am Sa - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Sector Gamma AS Has $2.74 Million Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Baillie Gifford & Co. Lowers Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial - TipRanks
BioNTech Shares Gain Momentum on Regulatory and Analyst Support () - aktiencheck.de
BNTX Stock Today: January 23 momentum after six-month high, 2026 catalysts - Meyka
BioNTech (BNTX) soars 11.8%: Is further upside left in the stock? - MSN
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Nasdaq
BioNTech (NASDAQ:BNTX) Trading 7.5% HigherHere's Why - MarketBeat
BioNTech’s BNT142 Trial Termination: What It Means for the Oncology Pipeline and Investors - TipRanks
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - yourwyominglink.com
What to Expect From Pfizer's Non-Oncology Business in Q4? - The Globe and Mail
BioNTech's Strategic Pivot: A Deep Dive into Its Expanding Oncology Pipeline () - aktiencheck.de
Goldman Sachs upgrades BioNTech stock to Buy on oncology potential - Investing.com
SG Americas Securities LLC Sells 69,726 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.58%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):